TransMedics Group Stock Forecast, Price & News

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

Is TransMedics Group a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group or view top-rated stocks.

How has TransMedics Group's stock been impacted by Coronavirus?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TMDX stock has increased by 59.0% and is now trading at $21.65.
View which stocks have been most impacted by COVID-19.

Are investors shorting TransMedics Group?

TransMedics Group saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,330,000 shares, an increase of 50.1% from the October 31st total of 886,200 shares. Based on an average trading volume of 224,500 shares, the days-to-cover ratio is presently 5.9 days. Currently, 5.4% of the shares of the company are short sold.
View TransMedics Group's Short Interest.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its earnings results on Tuesday, November, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.15. TransMedics Group had a negative net margin of 134.15% and a negative trailing twelve-month return on equity of 41.03%. During the same period in the prior year, the company earned ($0.19) earnings per share.
View TransMedics Group's earnings history.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $27.60 million-$28.60 million, compared to the consensus revenue estimate of $33.01 million.

What price target have analysts set for TMDX?

5 equities research analysts have issued 1 year price targets for TransMedics Group's stock. Their forecasts range from $30.00 to $79.00. On average, they anticipate TransMedics Group's stock price to reach $46.40 in the next twelve months. This suggests a possible upside of 114.3% from the stock's current price.
View analysts' price targets for TransMedics Group or view top-rated stocks among Wall Street analysts.

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:

• Waleed H. Hassanein, President, Chief Executive Officer & Director
• John F. Carey, Vice President-Operations (LinkedIn Profile)
• Stephen Gordon, Chief Financial Officer, Secretary & Treasurer (LinkedIn Profile)
• Mark Anderson, Senior Director-Technology Development
• John Sullivan, Vice President-Quality & Engineering

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Who are some of TransMedics Group's key competitors?

Some companies that are related to TransMedics Group include Outset Medical (OM), BioLife Solutions (BLFS), ViewRay (VRAY), Natus Medical (NTUS), Semler Scientific (SMLR), Cutera (CUTR), Stereotaxis (STXS), AxoGen (AXGN), Zynex (ZYXI), Edap Tms (EDAP), Electromed (ELMD), Movano (MOVE), FONAR (FONR), BioSig Technologies (BSGM) and IRIDEX (IRIX).
View all of TMDX's competitors.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.69%), Macquarie Group Ltd. (5.88%), Credit Suisse AG (5.49%), Bellevue Group AG (2.10%), Geode Capital Management LLC (1.58%) and Dimensional Fund Advisors LP (1.36%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends for TransMedics Group.

Which major investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Two Sigma Investments LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Dimensional Fund Advisors LP, Voloridge Investment Management LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc.. Company insiders that have sold TransMedics Group company stock in the last year include Abrams Capital Management, LP, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein.
View insider buying and selling activity for TransMedics Group or view top insider-selling stocks.

Which major investors are buying TransMedics Group stock?

TMDX stock was bought by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Moody Aldrich Partners LLC, Calamos Advisors LLC, Macquarie Group Ltd., Morgan Stanley, Russell Investments Group Ltd., US Bancorp DE, and Hsbc Holdings PLC.
View insider buying and selling activity for TransMedics Group or or view top insider-buying stocks.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $21.65.

How much money does TransMedics Group make?

TransMedics Group has a market capitalization of $601.18 million and generates $25.64 million in revenue each year. The company earns $-28.75 million in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 110 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

Where are TransMedics Group's headquarters?

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at (978) 552-0900 or via email at [email protected].